NEKTAR THERAPEUTICS
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
NKTR$37.78-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value information)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $44,252 | $35,277 |
| Short-term investments | 210,974 | 268,339 |
| Accounts receivable | — | 1,205 |
| Inventory | — | 16,101 |
| Other current assets | 6,066 | 9,779 |
| Total current assets | 261,292 | 330,701 |
| Long-term investments | 13,869 | 25,825 |
| Property, plant and equipment, net | 3,411 | 18,856 |
| Operating lease right-of-use assets | 8,413 | 18,007 |
| Equity method investment in Gannet BioChem | 12,218 | — |
| Other assets | 4,647 | 4,644 |
| Total assets | $303,850 | $398,033 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $11,560 | $9,848 |
| Accrued expenses (including $3,403 and $0, respectively, to a related party) | 29,972 | 22,162 |
| Operating lease liabilities, current portion | 19,868 | 19,259 |
| Total current liabilities | 61,400 | 51,269 |
| Operating lease liabilities, less current portion | 82,696 | 98,517 |
| Liabilities related to the sales of future royalties, net | 91,776 | 112,625 |
| Other long-term liabilities | 7,241 | 4,635 |
| Total liabilities | 243,113 | 267,046 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at December 31, 2024 or 2023, respectively | — | — |
| Common stock, $0.0001 par value; 300,000 shares authorized; 194,062 shares and 191,384 shares issued at December 31, 2024 and 2023, respectively; 185,777 shares and 191,384 shares outstanding at December 31, 2024 and 2023, respectively | 19 | 19 |
| Capital in excess of par value | 3,659,867 | 3,608,137 |
| Treasury stock, at cost; 8,285 shares as of December 31, 2024 and none as of December 31, 2023, respectively | (3,000) | — |
| Accumulated other comprehensive income (loss) | 61 | 80 |
| Accumulated deficit | (3,596,210) | (3,477,249) |
| Total stockholders’ equity | 60,737 | 130,987 |
| Total liabilities and stockholders’ equity | $303,850 | $398,033 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.